III~IV期または再発子宮内膜がんにおける通常の化学療法(パクリタキセルおよびカルボプラチン)への免疫療法薬ペムブロリズマブの追加の試験
測定可能なステージ III または IVA、ステージ IVB または再発子宮内膜がんに対する、パクリタキセルおよびカルボプラチンに加えてペムブロリズマブ (MK-3475、NSC #776864) の第 III 相無作為化プラセボ対照試験
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.
II. To evaluate blinded independent central review (BICR) assessed or investigator assessed objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by treatment arm and by mismatch repair (MMR) immunohistochemistry (IHC) status in patients who enter the study with measurable disease.
III. To evaluate BICR assessed or investigator assessed duration of response (DOR) by treatment arm and by MMR IHC status in patients who enter the study with measurable disease.
IV. To evaluate the effect of pembrolizumab (MK-3475) on overall survival (OS) in patients with mismatch repair protein proficient (pMMR) or mismatch repair deficiency (dMMR).
V. To determine whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with improved patient reported physical function as measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-physical function scale (short form), quality of life as measured with the Functional Assessment of Cancer Therapy (FACT) - Endometrial Trial Outcome Index (En TOI) and worsened fatigue as measured with the PROMIS-Fatigue scale (short form) in the pMMR patients.
VI. To determine concordance between institutional MMR IHC testing and centralized MMR IHC.
EXPLORATORY OBJECTIVES:
I. To explore the correlation between patient-reported physical function as measured with the PROMIS-physical function scale (short form) and quality of life as measure with the FACT-En TOI.
II. To explore whether the addition of pembrolizumab (MK-3475) to standard combination chemotherapy is associated with self-reported neurotoxicity as measured with the FACT/Gynecologic Oncology Group Neurotoxicity (GOG-Ntx) subscale (short) and the extent to which patients differ on their self-reported bother from side effects of cancer therapy in the pMMR patients.
III. To evaluate the efficacy of pembrolizumab (MK-3475) in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer by Programmed Death Ligand 1 (PD-L1) IHC (positive versus [vs] negative).
IV. To assess the association between PD-L1 IHC (positive vs negative) and mismatch repair status (pMMR and dMMR).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I:
COMBINATION PHASE: Patients receive placebo intravenously (IV) over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease may continue treatment for up to a total 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm I will not receive additional placebo infusions.
ARM II:
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
Patients undergo computed tomography (CT) scan throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Alaska Women's Cancer Care
-
-
Arizona
-
Goodyear、Arizona、アメリカ、85338
- CTCA at Western Regional Medical Center
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
-
California
-
Baldwin Park、California、アメリカ、91706
- Kaiser Permanente-Baldwin Park
-
Bellflower、California、アメリカ、90706
- Kaiser Permanente-Bellflower
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Clovis、California、アメリカ、93611
- Community Cancer Institute
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Harbor City、California、アメリカ、90710
- Kaiser Permanente South Bay
-
Irvine、California、アメリカ、92618
- Kaiser Permanente-Irvine
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
Lancaster、California、アメリカ、93534
- City of Hope Antelope Valley
-
Los Angeles、California、アメリカ、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Center
-
Los Angeles、California、アメリカ、90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles、California、アメリカ、90033
- Los Angeles General Medical Center
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange、California、アメリカ、92868
- Saint Joseph Hospital - Orange
-
Rancho Mirage、California、アメリカ、92270
- Eisenhower Medical Center
-
Redding、California、アメリカ、96001
- Mercy Regional Cancer Center
-
Redding、California、アメリカ、96002
- Mercy Oncology Center
-
Riverside、California、アメリカ、92505
- Kaiser Permanente-Riverside
-
Roseville、California、アメリカ、95661
- Kaiser Permanente-Roseville
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento、California、アメリカ、95814
- Kaiser Permanente Downtown Commons
-
Sacramento、California、アメリカ、95816
- Mercy Cancer Center - Sacramento
-
San Diego、California、アメリカ、92120
- Kaiser Permanente-San Diego Zion
-
San Diego、California、アメリカ、92134
- Naval Medical Center -San Diego
-
San Francisco、California、アメリカ、94115
- Kaiser Permanente-San Francisco
-
San Francisco、California、アメリカ、94158
- UCSF Medical Center-Mission Bay
-
San Francisco、California、アメリカ、94115
- California Pacific Medical Center-Pacific Campus
-
San Francisco、California、アメリカ、94110
- Zuckerberg San Francisco General Hospital
-
San Jose、California、アメリカ、95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro、California、アメリカ、94577
- Kaiser Permanente San Leandro
-
San Marcos、California、アメリカ、92078
- Kaiser Permanente-San Marcos
-
Santa Clara、California、アメリカ、95051
- Kaiser Permanente Medical Center - Santa Clara
-
South Pasadena、California、アメリカ、91030
- City of Hope South Pasadena
-
South San Francisco、California、アメリカ、94080
- Kaiser Permanente-South San Francisco
-
Sunnyvale、California、アメリカ、94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland、California、アメリカ、91786
- City of Hope Upland
-
Vallejo、California、アメリカ、94589
- Kaiser Permanente-Vallejo
-
Walnut Creek、California、アメリカ、94596
- Kaiser Permanente-Walnut Creek
-
Walnut Creek、California、アメリカ、94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs、Colorado、アメリカ、80909
- UCHealth Memorial Hospital Central
-
Colorado Springs、Colorado、アメリカ、80920
- Memorial Hospital North
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- Cancer Care and Hematology-Fort Collins
-
Greeley、Colorado、アメリカ、80631
- UCHealth Greeley Hospital
-
Greeley、Colorado、アメリカ、80631
- Banner North Colorado Medical Center
-
Loveland、Colorado、アメリカ、80538
- Medical Center of the Rockies
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Danbury、Connecticut、アメリカ、06810
- Danbury Hospital
-
Guilford、Connecticut、アメリカ、06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford、Connecticut、アメリカ、06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford、Connecticut、アメリカ、06102
- Hartford Hospital
-
New Britain、Connecticut、アメリカ、06050
- The Hospital of Central Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
North Haven、Connecticut、アメリカ、06473
- Yale-New Haven Hospital North Haven Medical Center
-
Norwalk、Connecticut、アメリカ、06856
- Norwalk Hospital
-
Stamford、Connecticut、アメリカ、06904
- Stamford Hospital/Bennett Cancer Center
-
Torrington、Connecticut、アメリカ、06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull、Connecticut、アメリカ、06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury、Connecticut、アメリカ、06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford、Connecticut、アメリカ、06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- Helen F Graham Cancer Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
Washington D.C.、District of Columbia、アメリカ、20016
- Sibley Memorial Hospital
-
-
Florida
-
Bradenton、Florida、アメリカ、34205
- Florida Cancer Specialists - Bradenton Cancer Center
-
Sarasota、Florida、アメリカ、34239
- Sarasota Memorial Hospital
-
Sarasota、Florida、アメリカ、34232
- Florida Cancer Specialists - Sarasota
-
Sarasota、Florida、アメリカ、34239
- Florida Cancer Specialists - Sarasota Downtown
-
Venice、Florida、アメリカ、34285
- Florida Cancer Specialists - Venice Island
-
Venice、Florida、アメリカ、34275
- Florida Cancer Specialists - Venice Pinebrook
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital Midtown
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30342
- Emory Saint Joseph's Hospital
-
Atlanta、Georgia、アメリカ、30303
- Grady Health System
-
Atlanta、Georgia、アメリカ、30342
- Northside Hospital
-
Austell、Georgia、アメリカ、30106
- WellStar Cobb Hospital
-
Fayetteville、Georgia、アメリカ、30214
- Piedmont Fayette Hospital
-
Gainesville、Georgia、アメリカ、30501
- Northeast Georgia Medical Center-Gainesville
-
Marietta、Georgia、アメリカ、30060
- Wellstar Kennestone Hospital
-
Marietta、Georgia、アメリカ、30060
- WellStar Health System Inc
-
Newnan、Georgia、アメリカ、30265
- CTCA at Southeastern Regional Medical Center
-
Roswell、Georgia、アメリカ、30076
- WellStar North Fulton Hospital
-
Savannah、Georgia、アメリカ、31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
Smyrna、Georgia、アメリカ、30080
- WellStar Vinings Health Park
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Queen's Medical Center
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Evanston、Illinois、アメリカ、60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva、Illinois、アメリカ、60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview、Illinois、アメリカ、60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey、Illinois、アメリカ、60426
- Ingalls Memorial Hospital
-
Highland Park、Illinois、アメリカ、60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
New Lenox、Illinois、アメリカ、60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Orland Park、Illinois、アメリカ、60462
- University of Chicago Medicine-Orland Park
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
Zion、Illinois、アメリカ、60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- Northwest Cancer Center - Crown Point
-
Dyer、Indiana、アメリカ、46311
- Northwest Oncology LLC
-
Hobart、Indiana、アメリカ、46342
- Northwest Cancer Center - Hobart
-
Hobart、Indiana、アメリカ、46342
- Saint Mary Medical Center
-
Indianapolis、Indiana、アメリカ、46237
- Franciscan Health Indianapolis
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis、Indiana、アメリカ、46219
- Community Cancer Center East
-
Indianapolis、Indiana、アメリカ、46227
- Community Cancer Center South
-
Indianapolis、Indiana、アメリカ、46256
- Community Cancer Center North
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
Indianapolis、Indiana、アメリカ、46312
- Saint Catherine Hospital
-
Mooresville、Indiana、アメリカ、46158
- Franciscan Health Mooresville
-
Munster、Indiana、アメリカ、46321
- The Community Hospital
-
Munster、Indiana、アメリカ、46321
- Women's Diagnostic Center - Munster
-
Valparaiso、Indiana、アメリカ、46383
- Northwest Cancer Center - Valparaiso
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- University of Kansas Clinical Research Center
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Cancer Center
-
Overland Park、Kansas、アメリカ、66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood、Kansas、アメリカ、66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Edgewood、Kentucky、アメリカ、41017
- Saint Elizabeth Healthcare Edgewood
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of The Lake
-
Baton Rouge、Louisiana、アメリカ、70817
- Woman's Hospital
-
Baton Rouge、Louisiana、アメリカ、70817
- Our Lady of the Lake Medical Oncology
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of the Lake Physician Group
-
Metairie、Louisiana、アメリカ、70006
- East Jefferson General Hospital
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
New Orleans、Louisiana、アメリカ、70112
- University Medical Center New Orleans
-
New Orleans、Louisiana、アメリカ、70115
- Ochsner Baptist Medical Center
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
Belfast、Maine、アメリカ、04915
- MaineHealth Waldo Hospital
-
Biddeford、Maine、アメリカ、04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer、Maine、アメリカ、04412
- Lafayette Family Cancer Center-EMMC
-
Rockport、Maine、アメリカ、04856
- Penobscot Bay Medical Center
-
Sanford、Maine、アメリカ、04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough、Maine、アメリカ、04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Annapolis、Maryland、アメリカ、21401
- Luminis Health Anne Arundel Medical Center
-
Baltimore、Maryland、アメリカ、21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital of Baltimore
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore、Maryland、アメリカ、21229
- Saint Agnes Hospital
-
Bel Air、Maryland、アメリカ、21014
- UM Upper Chesapeake Medical Center
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
Easton、Maryland、アメリカ、21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Clinic
-
Lowell、Massachusetts、アメリカ、01854
- Lowell General Hospital
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
Winchester、Massachusetts、アメリカ、01890
- Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
-
Worcester、Massachusetts、アメリカ、01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Flint、Michigan、アメリカ、48503
- Genesee Hematology Oncology PC
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Flint、Michigan、アメリカ、48503
- Cancer Hematology Centers - Flint
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
-
Minnesota
-
Bemidji、Minnesota、アメリカ、56601
- Sanford Joe Lueken Cancer Center
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
Jackson、Mississippi、アメリカ、39202
- Mississippi Baptist Medical Center
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital of Kansas City
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- Memorial Sloan Kettering Basking Ridge
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital University Medical Center
-
Lakewood、New Jersey、アメリカ、08701
- Monmouth Medical Center Southern Campus
-
Livingston、New Jersey、アメリカ、07039
- Cooperman Barnabas Medical Center
-
Long Branch、New Jersey、アメリカ、07740
- Monmouth Medical Center
-
Middletown、New Jersey、アメリカ、07748
- Memorial Sloan Kettering Monmouth
-
Montvale、New Jersey、アメリカ、07645
- Memorial Sloan Kettering Bergen
-
Neptune City、New Jersey、アメリカ、07753
- Jersey Shore Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
Paramus、New Jersey、アメリカ、07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood、New Jersey、アメリカ、07450
- Neurosurgeons of New Jersey-Ridgewood
-
Ridgewood、New Jersey、アメリカ、07450
- Valley Health System Ridgewood Campus
-
Somerville、New Jersey、アメリカ、08876
- Robert Wood Johnson University Hospital Somerset
-
Toms River、New Jersey、アメリカ、08755
- Community Medical Center
-
Voorhees Township、New Jersey、アメリカ、08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
Wayne、New Jersey、アメリカ、07470
- Valley Medical Group - Wayne Multispecialty Practice
-
Westwood、New Jersey、アメリカ、07675
- Valley Health System-Hematology/Oncology
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
-
New York
-
Bay Shore、New York、アメリカ、11706
- Northwell Health Imbert Cancer Center
-
Brightwaters、New York、アメリカ、11718
- Island Gynecologic Oncology
-
Brooklyn、New York、アメリカ、11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Commack、New York、アメリカ、11725
- Memorial Sloan Kettering Commack
-
Flushing、New York、アメリカ、11355
- The New York Hospital Medical Center of Queens
-
Harrison、New York、アメリカ、10604
- Memorial Sloan Kettering Westchester
-
Lake Success、New York、アメリカ、11042
- Northwell Health/Center for Advanced Medicine
-
Mineola、New York、アメリカ、11501
- NYU Langone Hospital - Long Island
-
New Hyde Park、New York、アメリカ、11040
- Long Island Jewish Medical Center
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York、New York、アメリカ、10065
- NYP/Weill Cornell Medical Center
-
New York、New York、アメリカ、10011
- Mount Sinai Chelsea
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
Rochester、New York、アメリカ、14620
- Highland Hospital
-
Staten Island、New York、アメリカ、10305
- Staten Island University Hospital
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
Uniondale、New York、アメリカ、11553
- Memorial Sloan Kettering Nassau
-
Valhalla、New York、アメリカ、10595
- Westchester Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Concord、North Carolina、アメリカ、28025
- Atrium Health Cabarrus/LCI-Concord
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville、North Carolina、アメリカ、28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Wilmington、North Carolina、アメリカ、28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Sanford Bismarck Medical Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44304
- Summa Health System - Akron Campus
-
Beachwood、Ohio、アメリカ、44122
- UHHS-Chagrin Highlands Medical Center
-
Canton、Ohio、アメリカ、44710
- Aultman Health Foundation
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Chardon、Ohio、アメリカ、44024
- Geauga Hospital
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44109
- MetroHealth Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Mentor、Ohio、アメリカ、44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania、Ohio、アメリカ、43560
- ProMedica Flower Hospital
-
West Chester、Ohio、アメリカ、45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake、Ohio、アメリカ、44145
- UH Seidman Cancer Center at Saint John Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend、Oregon、アメリカ、97701
- Saint Charles Health System
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland、Oregon、アメリカ、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
Tualatin、Oregon、アメリカ、97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Ephrata、Pennsylvania、アメリカ、17522
- Ephrata Cancer Center
-
Gettysburg、Pennsylvania、アメリカ、17325
- Adams Cancer Center
-
Hanover、Pennsylvania、アメリカ、17331
- WellSpan Medical Oncology and Hematology
-
Hazleton、Pennsylvania、アメリカ、18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Jefferson Hills、Pennsylvania、アメリカ、15025
- Jefferson Hospital
-
Johnstown、Pennsylvania、アメリカ、15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lancaster、Pennsylvania、アメリカ、17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster、Pennsylvania、アメリカ、17602
- Lancaster General Hospital
-
Lebanon、Pennsylvania、アメリカ、17042
- Sechler Family Cancer Center
-
Monroeville、Pennsylvania、アメリカ、15146
- Forbes Hospital
-
Monroeville、Pennsylvania、アメリカ、15146
- UPMC Hillman Cancer Center - Monroeville
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15224
- West Penn Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
Pittsburgh、Pennsylvania、アメリカ、15213
- UPMC-Magee Womens Hospital
-
Pottsville、Pennsylvania、アメリカ、17901
- Geisinger Cancer Services-Pottsville
-
Scranton、Pennsylvania、アメリカ、18510
- Community Medical Center
-
West Reading、Pennsylvania、アメリカ、19611
- Reading Hospital
-
Wexford、Pennsylvania、アメリカ、15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre、Pennsylvania、アメリカ、18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Willow Grove、Pennsylvania、アメリカ、19090
- Asplundh Cancer Pavilion
-
York、Pennsylvania、アメリカ、17403
- WellSpan Health-York Cancer Center
-
York、Pennsylvania、アメリカ、17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Rapid City Regional Hospital
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston、Texas、アメリカ、77070
- Methodist Willowbrook Hospital
-
Houston、Texas、アメリカ、77030
- Ben Taub General Hospital
-
Sugar Land、Texas、アメリカ、77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands、Texas、アメリカ、77385
- Houston Methodist The Woodlands Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City、Utah、アメリカ、84106
- University of Utah Sugarhouse Health Center
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Gig Harbor、Washington、アメリカ、98335
- MultiCare Gig Harbor Medical Park
-
Kennewick、Washington、アメリカ、99336
- Kadlec Clinic Hematology and Oncology
-
Puyallup、Washington、アメリカ、98372
- MultiCare Good Samaritan Hospital
-
Renton、Washington、アメリカ、98055
- Valley Medical Center
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Tacoma、Washington、アメリカ、98405
- MultiCare Tacoma General Hospital
-
Vancouver、Washington、アメリカ、98686
- Legacy Salmon Creek Hospital
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
Morgantown、West Virginia、アメリカ、26505
- Monongalia Hospital
-
-
Wisconsin
-
Burlington、Wisconsin、アメリカ、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown、Wisconsin、アメリカ、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、アメリカ、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、アメリカ、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、アメリカ、53142
- Aurora Cancer Care-Kenosha South
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette、Wisconsin、アメリカ、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh、Wisconsin、アメリカ、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、アメリカ、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、アメリカ、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、アメリカ、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Wauwatosa、Wisconsin、アメリカ、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
-
-
-
New Brunswick
-
Moncton、New Brunswick、カナダ、E1C 6Z8
- The Moncton Hospital
-
-
Ontario
-
Barrie、Ontario、カナダ、L4M 6M2
- Royal Victoria Regional Health Centre
-
Greater Sudbury、Ontario、カナダ、P3E 5J1
- Health Sciences North
-
Hamilton、Ontario、カナダ、L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston、Ontario、カナダ、K7L 2V7
- Kingston Health Sciences Centre
-
London、Ontario、カナダ、N6A 4L6
- London Regional Cancer Program
-
Oshawa、Ontario、カナダ、L1G 2B9
- Lakeridge Health Oshawa
-
Sault Ste. Marie、Ontario、カナダ、P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto、Ontario、カナダ、M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Laval、Quebec、カナダ、H7M 3L9
- Hopital de la Cite-de-la-Sante
-
Montreal、Quebec、カナダ、H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon、Saskatchewan、カナダ、S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
San Juan、プエルトリコ、00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
-
Saitama、日本、350-1298
- Saitama Medical University International Medical Center
-
-
Ehime
-
Tōon、Ehime、日本、791-0295
- Ehime University Hospital
-
-
Hiroshima
-
Kure、Hiroshima、日本、737
- Kure Medical Center and Chugoku Cancer Center
-
-
Niigata
-
Niigata、Niigata、日本、951-8520
- Niigata University Medical and Dental Hospital
-
-
-
-
-
Daegu、韓国、41404
- Kyungpook National University Chilgok Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、06273
- Gangnam Severance Hospital
-
Seoul、韓国、120-752
- Yonsei University Health System-Severance Hospital
-
Seoul、韓国、139-706
- Korea Cancer Center Hospital
-
-
Daegu
-
Dalseo-gu、Daegu、韓国、42601
- Keimyung University-Dongsan Medical Center
-
-
Gyeongsangnam-do
-
Seoul、Gyeongsangnam-do、韓国、51353
- Samsung Changwon Hospital
-
-
Kyeonggi-do
-
Seongnam、Kyeonggi-do、韓国、463-707
- Seoul National University Bundang Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.
-
Pathology report showing results of institutional MMR IHC testing.
-
Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.).
-
Submission of tumor specimens for centralized MMR IHC testing is required after Step 1 and before Step 2 registration.
-
In patients with measurable disease, lesions will be defined and monitored by RECIST version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
-
Patients may have received
- NO prior chemotherapy for treatment of endometrial cancer OR
- Prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) provided adjuvant chemotherapy was completed >= 12 months prior to STEP 2 registration.
-
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to STEP 2 registration.
-
Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to STEP 2 registration.
-
Interval or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted.
-
Age >= 18.
-
Performance status of 0, 1 or 2.
-
Platelets >= 100,000/mcl.
-
Absolute neutrophil count (ANC) >= 1,500/mcl.
-
Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN).
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled).
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN.
-
Thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal Free T4 level is required.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 2 registration are eligible for this trial.
-
For patients of child bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
-
Administration of study drugs (pembrolizumab [MK-3475], paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from at least 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:
- Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR
- Have a congenital or acquired condition that prevents childbearing.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.
Exclusion Criteria:
-
Patients with prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
-
Patients who have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab (MK-3475) and/or its excipients; and/or a severe hypersensitivity reaction to paclitaxel and/or carboplatin.
-
Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration.
-
Patients who have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Step 2 registration.
- Patients who have received steroids as CT scan contrast premedication may be enrolled.
- The use of inhaled or topical corticosteroids is allowed.
- The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
- The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 2 registration and remain clinically stable.
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to, patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease.
-
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
-
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Pregnant or lactating patients.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm I (placebo, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions. |
Given IV
他の名前:
Given IV
他の名前:
Ancillary studies
他の名前:
Given IV Ancillary studies Undergo CT scan
他の名前:
|
|
実験的:Arm II (pembrolizumab, paclitaxel, carboplatin)
COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study. |
Given IV
他の名前:
Given IV
他の名前:
Ancillary studies
他の名前:
Ancillary studies Given IV
他の名前:
Undergo CT scan
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS)
時間枠:Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
Progression free survival (PFS) Note: For arm 2 (dMMR Cohort), the point estimate and the upper limit of the confidence interval are not able to be estimated due to insufficient events. |
Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse Events With Grade 3 (or Higher)
時間枠:For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE V5.0). The endpoint is the count of participants with an adverse event of grade 3 (or higher) by treatment group. |
For the adverse event time frame, the interquartile range was (0.79 months, 3.42 months); the maximum was 28.39 months.
|
|
Objective Tumor Response
時間枠:For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1. |
For the time frame for tumor response, the interquartile range was (2.27 months, 8.66 months) and the maximum was 36.37 months.
|
|
Duration of Objective Response
時間枠:For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
The time difference between the dates of first response and first progression; patients who do not progress are considered censored. Note: for Arm 2 (dMMR Cohort), the upper limit of the confidence interval is not able to be estimated due to an insufficient number of events. |
For the duration of objective response, the interquartile range is (4.24 months, 7.92 months); the maximum is 28.68 months.
|
|
Overall Survival (OS)
時間枠:Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall Survival (OS). This endpoint will be assessed by Kaplan-Meier. |
Time from study entry to time of death or the date of last contact, assessed up to 5 years
|
|
Quality of Life (QoL) in pMMR Patients Only
時間枠:0-54 weeks from start of treatment
|
QoL are collected in pMMR patients only and measured with the Function Assessment of Cancer Therapy -Endometrial Trial Outcome Index (FACT En-TOI). The FACT-En TOI scores range 0 - 120 with a larger score suggesting better or favorable state of QOL. |
0-54 weeks from start of treatment
|
|
Concordance Between Institutional Mismatch Repair (MMR) Immunohistochemistry (IHC) Testing and Centralized MMR IHC
時間枠:IHC testing values (for both central and institutional) were collected at baseline.
|
Concordance between institutional MMR IHC testing and centralized MMR IHC. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics including the kappa statistic (e.g. Cohen's kappa coefficient). |
IHC testing values (for both central and institutional) were collected at baseline.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity
時間枠:0-54 weeks from start of treatment
|
Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form). |
0-54 weeks from start of treatment
|
|
Effect of Pembrolizumab on PFS and OS by Program Death Ligand 1 (PD-L1) IHC
時間枠:5 years
|
Will assess the effect of pembrolizumab on PFS and OS by PD-L1 (combined positive score [CPS]) within proficient MMR (pMMR) and deficient MMR (dMMR) populations. The effectiveness of pembrolizumab will be compared by PD-L1 status (CPS). A formal test will be conducted by examining the interaction term between pembrolizumab treatment (yes or no) with PD-L1 status. The association between PD-L1 CPS status and MMR IHC status will be assessed with odds ratios. A test may be conducted with a Fisher's Exact Test, and confidence intervals will be provided. |
5 years
|
|
Association Between PD-L1 IHC and MMR Status
時間枠:5 years
|
Measures of association between PD-L1 IHC (CPS) and MMR IHC status. The concordance of institutional MMR IHC testing and centralized MMR IHC will be characterized by agreement statistics such as kappa statistics (e.g. Cohen's kappa coefficient). |
5 years
|
協力者と研究者
捜査官
- 主任研究者:Ramez N Eskander、NRG Oncology
出版物と役立つリンク
一般刊行物
- Morton M, Marcu I, Levine M, Cosgrove C, Backes F, O'Malley D, Chambers L. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Obstet Gynecol. 2023 Aug 1;142(2):360-363. doi: 10.1097/AOG.0000000000005243. Epub 2023 Jul 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5.
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27.
- Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2019-02186
- U10CA180868 (米国 NIH グラント/契約)
- NCI-2019-02186 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- NRG-GY018 (その他の識別子:CTEP)
- NRG-GY018 (その他の識別子:NRG Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。